
Depending on dose, firmonertinib shrank tumors in 43% to 68% of patients as a first treatment for EGFR PACC-mutant lung cancer in the phase 1b FURTHER trial.
Black patients with early-stage lung cancer were less likely to receive curative treatment than White patients, despite all having Medicare coverage, study finds.
Dr. Olivia Lynch, a postdoctoral fellow in the National Clinician Scholars Program at Yale University, highlighted findings from a study of more than 28,000 Medicare beneficiaries with early-stage non-small cell lung cancer.






